Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, AMNEAL PHARMACEUTICALS, INC. reported revenue of $3.02B, up 8.0% year over year. Operating margin was 13.1% and net margin 2.4%, on a free-cash-flow margin of 8.9% with capital expenditure at 2.3% of revenue. Every figure is computed directly from AMRX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $3.02B | 13.1% | 2.4% |
| FY2024 | $2.79B | 8.9% | -4.2% |
| FY2023 | $2.39B | 8.5% | -3.5% |
| FY2022 | $2.21B | -4.3% | -12.2% |
| FY2021 | $2.09B | 7.3% | 0.6% |
How does AMRX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.